UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
39.01 USD
+0.97 (+2.55%)
Last:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- UTI had positive earnings in the past year.
- In the past year UTI had a positive cash flow from operations.
- Each year in the past 5 years UTI has been profitable.
- In the past 5 years UTI always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.44%, UTI is in the better half of the industry, outperforming 73.97% of the companies in the same industry.
- With a decent Return On Equity value of 15.98%, UTI is doing good in the industry, outperforming 75.34% of the companies in the same industry.
- The Return On Invested Capital of UTI (8.69%) is better than 76.71% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for UTI is below the industry average of 10.75%.
- The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- With a decent Profit Margin value of 6.28%, UTI is doing good in the industry, outperforming 65.75% of the companies in the same industry.
- In the last couple of years the Profit Margin of UTI has grown nicely.
- The Operating Margin of UTI (8.38%) is better than 67.12% of its industry peers.
- UTI's Operating Margin has improved in the last couple of years.
- UTI has a Gross Margin (49.62%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of UTI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- UTI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- UTI has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, UTI has more shares outstanding
- The debt/assets ratio for UTI has been reduced compared to a year ago.
2.2 Solvency
- UTI has an Altman-Z score of 4.07. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- UTI's Altman-Z score of 4.07 is fine compared to the rest of the industry. UTI outperforms 79.45% of its industry peers.
- UTI has a debt to FCF ratio of 6.28. This is a slightly negative value and a sign of low solvency as UTI would need 6.28 years to pay back of all of its debts.
- UTI has a better Debt to FCF ratio (6.28) than 71.23% of its industry peers.
- A Debt/Equity ratio of 0.29 indicates that UTI is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.29, UTI is in line with its industry, outperforming 58.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 4.07 |
ROIC/WACC0.98
WACC8.83%
2.3 Liquidity
- A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI has a Current ratio of 1.14. This is comparable to the rest of the industry: UTI outperforms 46.58% of its industry peers.
- A Quick Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI's Quick ratio of 1.14 is in line compared to the rest of the industry. UTI outperforms 49.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- The earnings per share for UTI have decreased by 0.00% in the last year.
- The Earnings Per Share has been growing by 65.96% on average over the past years. This is a very strong growth
- UTI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.59%.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- The Earnings Per Share is expected to grow by 5.89% on average over the next years.
- UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.84% yearly.
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 40.22, UTI can be considered very expensive at the moment.
- UTI's Price/Earnings ratio is in line with the industry average.
- UTI is valuated expensively when we compare the Price/Earnings ratio to 25.54, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 42.48 indicates a quite expensive valuation of UTI.
- UTI's Price/Forward Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, UTI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.22 | ||
| Fwd PE | 42.48 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as UTI.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTI indicates a somewhat cheap valuation: UTI is cheaper than 60.27% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 132.99 | ||
| EV/EBITDA | 18.59 |
4.3 Compensation for Growth
- UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.61
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- UTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
NYSE:UTI (3/24/2026, 3:17:24 PM)
39.01
+0.97 (+2.55%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-05 2026-05-05
Inst Owners97.17%
Inst Owner Change7.31%
Ins Owners2.7%
Ins Owner Change3.59%
Market Cap2.15B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (-1.51%)
Short Float %6.37%
Short Ratio4.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0.64%
PT rev (3m)0.64%
EPS NQ rev (1m)-109.53%
EPS NQ rev (3m)-103.82%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-1.83%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.45%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.22 | ||
| Fwd PE | 42.48 | ||
| P/S | 2.51 | ||
| P/FCF | 132.99 | ||
| P/OCF | 27.71 | ||
| P/B | 6.39 | ||
| P/tB | 7.49 | ||
| EV/EBITDA | 18.59 |
EPS(TTM)0.97
EY2.49%
EPS(NY)0.92
Fwd EY2.35%
FCF(TTM)0.29
FCFY0.75%
OCF(TTM)1.41
OCFY3.61%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.61
Graham Number11.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 4.07 |
F-Score7
WACC8.83%
ROIC/WACC0.98
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
Can you provide the financial health for UTI stock?
The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 5 / 10.
What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.